NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it is collaborating with Merck KGaA to use its MGMT gene promoter methylation technology to select patients for trials for drugs to treat glioblastoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.